1,573 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDXFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,573 shares of the medical instruments supplier’s stock, valued at approximately $383,000.

Other hedge funds have also recently modified their holdings of the company. Ontario Teachers Pension Plan Board boosted its holdings in Becton, Dickinson and Company by 242.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the last quarter. Vanguard Group Inc. grew its holdings in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after acquiring an additional 516,427 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Becton, Dickinson and Company by 11.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after acquiring an additional 512,566 shares during the period. Royal Bank of Canada lifted its stake in shares of Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after purchasing an additional 473,914 shares during the period. Finally, Morgan Stanley grew its position in Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after buying an additional 435,168 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Separately, Barclays lifted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $281.40.

Check Out Our Latest Research Report on BDX

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $2.40 during midday trading on Wednesday, hitting $237.40. The company’s stock had a trading volume of 481,341 shares, compared to its average volume of 1,406,909. The company has a market cap of $68.61 billion, a P/E ratio of 52.02, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The business’s 50 day simple moving average is $238.21 and its 200 day simple moving average is $239.26. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the prior year, the business earned $2.86 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. On average, analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.60%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.